An FP’s guide to caring for patients with seizure and epilepsy

,; ,; ,; ,; ,

doi:doi: 10.12788/jfp.0685

Applied Evidence

An FP’s guide to caring for patients with seizure and epilepsy

J Fam Pract. 2023 November;72(9):366-373,385 | doi: 10.12788/jfp.0685

PDF Download

References

1. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc. 1996;71:576-586. doi: 10.4065/71.6.576

2. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475-482. doi: 10.1111/epi.12550.

3. Hauser WA, Beghi E. First seizure definitions and worldwide incidence and mortality. Epilepsia. 2008;49:8-12. doi: 10.1111/j.1528-1167.2008.01443.x

4. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology. 1991;41:965-972. doi: 10.1212/wnl.41.7.965

5. Ropper AH. Transient global amnesia. N Engl J Med. 2023;388:635-540. doi: 10.1056/NEJMra2213867

6. Bouma HK, Labos C, Gore GC, et al. The diagnostic accuracy of routine electroencephalography after a first unprovoked seizure. Eur J Neurol. 2016;23:455-463. doi: 10.1111/ene.12739

7. Narayanan JT, Labar DR, Schaul N. Latency to first spike in the EEG of epilepsy patients. Seizure. 2008;17:34-41. doi: 10.1016/j.seizure.2007.06.003

8. Salmenpera TM, Duncan JS. Imaging in epilepsy. J Neurol Neurosurg Psychiatry. 2005;76:iii2-iii10. doi: 10.1136/jnnp.2005.075135

9. Jackson GD, Berkovic SF, Tress BM, et al. Hippocampal sclerosis can be reliably detected by magnetic resonance imaging. Neurology. 1990;40:1869-1875. doi: 10.1212/wnl.40.12.1869

10. Bonnett LJ, Kim, L, Johnson A, et al. Risk of seizure recurrence in people with single seizures and early epilepsy - model development and external validation. Seizure. 2022;94:26-32. doi: 10.1016/j.seizure.2021.11.007

11. Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2015;84:1705-1713. doi: 10.1212/WNL.0000000000001487

12. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and terminology. Epilepsia. 2017;58:522-530. doi: 10.1111/epi.13670

13. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsy: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51:676-685. doi: 10.1111/j.1528-1167.2010.02522.x

14. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblinded randomized controlled trial. Lancet. 2007;369:1016-1026. doi: 10.1016/S0140-6736(07)60461-9

15. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomized controlled trial. Lancet 2007;369:1000-1015. doi: 10.1016/S0140-6736(07)60460-7

16. Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalized and unclassified epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomized controlled trial. Lancet. 2021;397:1375-1386. doi: 10.1016/S0140-6736(21)00246-4

17. Mawhinney E, Craig J, Morrow J. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology. 2013;80:400-405.

18. Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomized controlled trial. Lancet. 2021;397:1363-1374. doi: 10.1016/S0140-6736(21)00247-6

19. Smith PE. Initial management of seizure in adults. N Engl J Med. 2021;385:251-263. doi: 10.1056/NEJMcp2024526

20. Depakene (valproic acid). Package insert. Abbott Laboratories; 2011. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2011/018081s046_18082s031lbl.pdf

21. Greenberg RG, Melloni C, Wu H, et al. Therapeutic index estimation of antiepileptic drugs: a systematic literature review approach. Clin Neuropharmacol. 2016;39:232-240. doi: 10.1097/WNF.0000000000000172

22. Lamictal (lamotrigine). Package insert. GlaxoSmithKline; 2009. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2009/020241s037s038,020764s030s031lbl.pdf

23. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA. 2004;291:605-614. doi: 10.1001/jama.291.5.605

24. Topamax (topiramate). Package insert. Janssen Pharmaceuticals, Inc. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2012/020844s041lbl.pdf

25. Keppra (levetiracetam). Package insert. UCB, Inc.; 2009. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2009/021035s078s080%2C021505s021s024lbl.pdf

26. Carbatrol (carbamazepine). Package insert. Shire US Inc; 2013. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2013/020712s032s035lbl.pdf

27. Neurontin (gabapentin). Package insert. Pfizer; 2017. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf

28. Zonegran (zonisamide). Package insert. Eisai Inc; 2006. Accessed October 6, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2006/020789s019lbl.pdf

29. Gloss D, Paragon K, Pack A, et al. Antiseizure medication withdrawal in seizure-free patients: practice advisory update. Report of the AAN Guideline Subcommittee. Neurology. 2021;97:1072-1081. doi: 10.1212/WNL.0000000000012944

30. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000:342:314-319. doi: 10.1056/NEJM200002033420503

31. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069-1077. doi: 10.1111/j.1528-1167.2009.02397.x

32. Leppik IE. Compliance during treatment of epilepsy. Epilepsia 1988;29(suppl 2):S79-S84.

33. Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: a systematic review. Neurology. 2015;13;85:1332-1341. doi: 10.1212/WNL.0000000000002023

34. Singh G, Rees JH, Sander JW. Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. JNNP. 2007;78:342-349. doi: 10.1136/jnnp.2006.106211

35. Pisani F, Oteri G, Costa C., et al. Effects of psychotropic drugs on seizure threshold. Drug Safety. 2002;25:91-110.

36. Rossi KC, Joe J, Makhjia M, et al. Insufficient sleep, electroencephalogram activation, and seizure risk: re-evaluating the evidence. Ann Neurol. 2020;86:798-806. doi: 10.1002/ana.25710

37. Watson NF, Badr MS, Belenky G, et al. Recommended amount of sleep for a healthy adult: a Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep. 2015;38:843-844. doi: 10.5665/sleep.4716

38. Höppener RJ, Kuyer A, van der Lugt PJ. Epilepsy and alcohol: the influence of social alcohol intake on seizures and treatment in epilepsy. Epilepsia. 1983;24:459-471. doi: 10.1111/j.1528-1157.1983.tb04917.x

39. Keeler MH, Reifler CB. Grand mal convulsions subsequent to marijuana use. Case report. Dis Nerv Syst. 1967:28:474-475.

40. Epidiolex (cannabidiol). Package insert. Greenwich Biosciences Inc; 2018. Accessed September 27, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf

41. ClinicalTrials.gov. Maternal Outcomes and Neurodevelopmental Effects of Antiseizure Drugs (MONEAD). Accessed September 24, 2023. https://classic.clinicaltrials.gov/ct2/show/NCT01730170

42. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology. 2006;67:407-412. doi: 10.1212/01.wnl.0000227919.81208.b2

43. Meador K, Reynolds MW, Crean S. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008;81:1-13. doi:10.1016/j.eplepsyres.2008.04.022

44. Marxer CA, Rüegg S, Rauch MS, et al. A review of the evidence on the risk of congenital malformations and neurodevelopmental disorders in association with antiseizure medications during pregnancy. Expert Opin Drug Saf. 2021;20:1487-1499. doi: 10.1080/14740338.2021.1943355

45. Asadi-Pooya AA, Sperling MR. Epidemiology of psychogenic nonepileptic seizures. Epilepsy Behav. 2015;46:60-65. doi: 10.1016/j.yebeh.2015.03.015

46. Beimer NJ, LaFrance Jr WC. Evaluation and treatment of psychogenic nonepileptic seizures. Neurol Clin. 2022;40:799-820. doi: 10.1016/j.ncl.2022.03.017

47. Motamedi GK. Psychogenic nonepileptic seizures: a disconnect between body and mind. Epilepsy Behav. 2018;78:293-294. doi: 10.1016/j.yebeh.2017.10.016

48. Chang AK, Shinnar S. Nonconvulsive status epilepticus. Emerg Med Clin North Am. 2011;29:65-72. doi: 10.1016/j.emc.2010.08.006

49. AAP Practice Guideline. Neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics. 2011;127:389-394. doi: 10.1542/peds.2010-3318

50. Chin RF, Neville BG, Peckham C, et al. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet. 2006;368:222-229. doi: 10.1016/S0140-6736(06)69043-0

51. McTague A, Martland T, Appleton R. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Sys Rev. 2018;1(1):CD001905. doi: 10.1002/14651858.CD001905.pub3

52. Jensen FE. Epilepsy as a spectrum disorder: implications from novel clinical and basic neuroscience. Epilepsia. 2011;52(suppl 1):1-6. doi: 10.1111/j.1528-1167.2010.02904.x

53. Kass JS, Rose RV. Driving and epilepsy: ethical, legal, and health care policy challenges. Continuum (Minneap Minn). 2019;25:537-542. doi: 10.1212/CON.0000000000000714

54. Troxell J. Epilepsy and employment: the Americans with Disabilities Act and its protections against employment discrimination. Med Law. 1997;16:375-384.

Medications may provoke seizures in susceptible individuals (TABLE 2^33-35).

Sleep deprivation is a potential seizure trigger in people with epilepsy based on observational studies, case reports, patient surveys, and EEG-based studies, although data from randomized controlled studies are limited.³⁶ The standard best practice is to encourage appropriate sleep hygiene, which involves getting at least 7 hours of sleep per night.³⁷

Alcohol is a GABAergic substance like benzodiazepines with antiseizure effects. However, it acts as a potential precipitant of seizures in cases of withdrawal or acute intoxication, or when it leads to sleep disruption or nonadherence to antiseizure medications. Therefore, advise patients with alcohol use disorder to slowly taper consumption (best done through a support program) and avoid sudden withdrawal. However, complete abstinence from alcohol use is not often recommended except in special circumstances (eg, a history of alcohol-related seizures). Several studies have demonstrated that modest alcohol use (1-2 drinks per occasion) does not increase seizure frequency or significantly alter serum concentrations of commonly used ASMs.³⁸

Cannabis and other substances. The 2 main biologically active components of marijuana are delta-9-tetrahydrocannibinol (THC), the main psychoactive constituent, and cannabidiol (CBD). Animal and human studies have demonstrated anticonvulsant properties of THC and CBD. But THC, in high amounts, can result in adverse cognitive effects and worsening seizures.³⁹ A purified 98% oil-based CBD extract (Epidiolex) has been approved as an adjunctive treatment for certain medically refractory epilepsy syndromes in children and young adults—ie, Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex syndrome.⁴⁰ There are no reliable data on the effect of recreational use of marijuana on seizure control. Other illicit substances such as cocaine may lower seizure threshold by their stimulatory and disruptive effects on sleep, diet, and healthy routines.

Special clinical cases

Pregnancy and epilepsy

Despite the potential adverse effects of ASMs on fetal health, the current global consensus is to continue treatment during pregnancy, given that the potential harm of convulsive seizures outweighs the potential risks associated with in-utero exposure to ASMs. There is not enough evidence to indicate significant harm to the fetus caused by focal, absence, or myoclonic seizures. Low-dose folic acid is used to minimize the risks of ASMs during pregnancy.

Continue to: As the fetus develops...